Our Work Focuses on One Thing: Giving Hope to Patients Suffering from Cancer
CVBio is a clinical-stage biotechnology company pioneering virus-driven immunotherapies for hard-to-treat cancers, with a focus on tumors resistant to conventional treatments. Our approach is a proprietary platform based on a genetically engineered adenovirus derived from the common cold virus. This unique backbone enables the creation of powerful, targeted therapies that are designed to selectively destroy tumor cells while activating the body’s immune system to mount a durable, systemic antitumor response.
The platform operates through a dual mechanism of action: It first replicates within tumor cells to induce direct cell death (oncolysis), and it then initiates a robust immune response by recruiting key immune cells—such as cytotoxic T-cells and macrophages—into the tumor microenvironment. This combination of targeted oncolysis and immune activation has been shown in clinical trials to be both well tolerated and able to lead to sustained anticancer activity.
CVBio’s Platform Offers Several Key Advantages:
- Novel Mechanism: Direct tumor killing combined with immune activation
- Versatility: Adaptable for a wide range of cancers
- Favorable Safety Profile: Demonstrated in multiple clinical trials
- Combination Potential: Easily integrated with other treatment modalities
By combining cutting-edge virology with immuno-oncology, CVBio is advancing a new frontier in cancer therapy—bringing hope to patients with limited treatment options.
CVBio’s pipeline includes two clinical-stage candidates:
DNX-2401 (tasadenoturev)
DNX-2401 (tasadenoturev) is an oncolytic adenovirus engineered to infect, replicate in, and destroy cancer cells while stimulating a systemic immune response. It is currently being evaluated for aggressive brain tumors, including recurrent glioblastoma in adults and diffuse intrinsic pontine glioma (DIPG) in children. Clinical studies have shown extended survival in glioblastoma patients and a favorable safety profile. DNX-2401 has received Fast Track and Orphan Drug designations from the FDA and PRIME and Orphan status from the EMA.
Combination Therapies
CVBio has the potential to advance additional pipeline candidates leveraging its versatile platform technology.
By encoding powerful immune modulators, such as T-cell agonists, Treg antagonists, and checkpoint inhibitors, in its virus-driven platform, the company can develop therapeutic armed viruses.
The first candidates, expressing members of the tumor necrosis factor receptor superfamily that enhance T-cell activity, show remarkable efficacy in animal models of cancer, including breast, skin, brain, and lung.
CVBio is continuing to expand its pipeline with additional potent molecules and approaches to treat cancers that are resistant to currently available therapies.
News and Resources
